We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Unilever
UL
$135B
| $238K | ﹤0.01% |
3,739
-72
| -2% | -$4.86K |
|
477
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
| $217K | ﹤0.01% |
+2,653
| New | +$218K |
|
478
Verizon
VZ
$195B
| $217K | ﹤0.01% |
5,437
-918
| -14% | -$38.7K |
|
479
Equinix
EQIX
$103B
| $215K | ﹤0.01% |
228
+34
| +18% | +$31.3K |
|
480
Texas Instruments
TXN
$256B
| $212K | ﹤0.01% |
1,133
-475,889
| -100% | -$95.1M |
|
481
ConocoPhillips
COP
$148B
| $202K | ﹤0.01% |
2,039
+86
| +4% | +$9.13K |
|
482
NextEra Energy
NEE
$177B
| $201K | ﹤0.01% |
2,802
+46
| +2% | +$3.57K |
|
483
iShares Russell 2000 Growth ETF
IWO
$14.9B
| $194K | ﹤0.01% |
674
+130
| +24% | +$38.5K |
|
484
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$48.4B
| $192K | ﹤0.01% |
451
| – | – |
|
485
Philip Morris
PM
$290B
| $190K | ﹤0.01% |
1,579
-315
| -17% | -$39.7K |
|
486
iShares Core S&P 500 ETF
IVV
$904B
| $188K | ﹤0.01% |
320
+210
| +191% | +$124K |
|
487
Palantir
PLTR
$421B
| $186K | ﹤0.01% |
2,465
-21
| -0.8% | -$1.22K |
|
488
Blackstone
BX
$113B
| $177K | ﹤0.01% |
1,027
+79
| +8% | +$13.8K |
|
489
iShares S&P 500 Growth ETF
IVW
$77.4B
| $173K | ﹤0.01% |
1,704
+1,696
| +21,200% | +$169K |
|
490
Chipotle Mexican Grill
CMG
$40.7B
| $153K | ﹤0.01% |
2,544
+902
| +55% | +$54.4K |
|
491
Medtronic
MDT
$114B
| $152K | ﹤0.01% |
1,900
-282
| -13% | -$24.4K |
|
492
DraftKings
DKNG
$12B
| $149K | ﹤0.01% |
4,018
| – | – |
|
493
Pfizer
PFE
$154B
| $148K | ﹤0.01% |
5,597
-2,853
| -34% | -$77.4K |
|
494
iShares US Industrials ETF
IYJ
$1.94B
| $146K | ﹤0.01% |
1,095
+286
| +35% | +$39.3K |
|
495
American Electric Power
AEP
$66.9B
| $143K | ﹤0.01% |
1,548
+706
| +84% | +$68.3K |
|
496
Prologis
PLD
$132B
| $142K | ﹤0.01% |
1,346
+113
| +9% | +$13K |
|
497
Amgen
AMGN
$226B
| $141K | ﹤0.01% |
541
-313
| -37% | -$92.9K |
|
|
BNY
498
Bank of New York Mellon
BNY
$108B
| $141K | ﹤0.01% |
1,840
+446
| +32% | +$34.5K |
|
499
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| $140K | ﹤0.01% |
239
| – | – |
|
500
Paychex
PAYX
$43.1B
| $136K | ﹤0.01% |
967
+362
| +60% | +$51.4K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.